| Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) L Ferreira, E Teixeira-de-Lemos, F Pinto, B Parada, C Mega, H Vala, ... Mediators of inflammation 2010 (1), 592760, 2010 | 293 | 2010 |
| Survival with cemiplimab in recurrent cervical cancer KS Tewari, BJ Monk, I Vergote, A Miller, AC de Melo, HS Kim, YM Kim, ... New England Journal of Medicine 386 (6), 544-555, 2022 | 240 | 2022 |
| Triple negative breast cancer: A thorough review of biomarkers JL da Silva, NCC Nunes, P Izetti, GG de Mesquita, AC de Melo Critical reviews in oncology/hematology 145, 102855, 2020 | 233 | 2020 |
| A Voice-Assisted Approach for Vehicular Data Querying from Automotive IoT-Based Databases M Andrade, E Wanderley, M Azevedo, T Medeiros, M Silva, I Silva, ... 2023 Symposium on Internet of Things (SIoT), 1-5, 2023 | 177 | 2023 |
| Sucesso e desenvolvimento psicológico no Ensino Superior: Estratégias de intervenção AMS Pereira, ED Motta, AL Vaz, C Pinto, O Bernardino, AC de Melo, ... Análise psicológica 24 (1), 51-59, 2006 | 151 | 2006 |
| Challenges in the diagnosis and treatment of gestational trophoblastic neoplasia worldwide A Braga, P Mora, AC de Melo, A Nogueira-Rodrigues, J Amim-Junior, ... World journal of clinical oncology 10 (2), 28, 2019 | 105 | 2019 |
| Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label … R Kristeleit, A Lisyanskaya, A Fedenko, M Dvorkin, AC de Melo, ... The Lancet Oncology 23 (4), 465-478, 2022 | 99 | 2022 |
| Cancer inpatients with COVID-19: A report from the Brazilian National Cancer Institute AC de Melo, LCS Thuler, JL da Silva, LZ de Albuquerque, AC Pecego, ... PloS one 15 (10), e0241261, 2020 | 85 | 2020 |
| Cancer immunotherapy: the art of targeting the tumor immune microenvironment JL da Silva, ALS Dos Santos, NCC Nunes, F de Moraes Lino da Silva, ... Cancer Chemotherapy and Pharmacology 84, 227-240, 2019 | 65 | 2019 |
| A review of mTOR pathway inhibitors in gynecologic cancer AC de Melo, E Paulino, ÁHI Garces Oxidative Medicine and Cellular Longevity 2017 (1), 4809751, 2017 | 63 | 2017 |
| Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years AC de Melo, AJA Wainstein, AC Buzaid, LCS Thuler Melanoma Research 28 (6), 629-636, 2018 | 61 | 2018 |
| Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data R Park, SA Lee, SY Kim, AC de Melo, A Kasi Acta Oncologica 60 (1), 13-19, 2021 | 57 | 2021 |
| Sars-CoV-2/Covid-19 em pacientes com câncer LCS Thuler, AC de Melo Revista brasileira de cancerologia 66 (2), 2020 | 57 | 2020 |
| Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E … SN Westin, K Moore, HS Chon, JY Lee, J Thomes Pepin, M Sundborg, ... Journal of Clinical Oncology 42 (3), 283-299, 2024 | 51 | 2024 |
| Determinants of COVID-19 mortality in patients with cancer from a community oncology practice in Brazil BL Ferrari, CG Ferreira, M Menezes, P De Marchi, J Canedo, AC Melo, ... JCO global oncology 7, 46-55, 2021 | 48 | 2021 |
| VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic … KS Tewari, BJ Monk, I Vergote, A Miller, AC De Melo, HS Kim, YM Kim, ... Annals of Oncology 32 (7), 940-941, 2021 | 45 | 2021 |
| Treatment of ovarian cancer beyond chemotherapy: are we hitting the target? ÁHI Garces, MSF Dias, E Paulino, CGM Ferreira, AC de Melo Cancer chemotherapy and pharmacology 75, 221-234, 2015 | 44 | 2015 |
| Linfoma não-Hodgkin de alto grau-Revisão da literatura LH de Lima Araújo, APO de Souza Victorino, AC de Melo, DX Assad, ... Revista brasileira de cancerologia 54 (2), 175-183, 2008 | 43 | 2008 |
| Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer VH de Almeida, I dos Santos Guimarães, LR Almendra, AMR Rondon, ... Oncotarget 9 (55), 30594, 2018 | 41 | 2018 |
| Mutational profile and new IASLC/ATS/ERS classification provide additional prognostic information about lung adenocarcinoma: a study of 125 patients from Brazil AC De Melo, V Karen de Sá, C Sternberg, ER Olivieri, ... Oncology 89 (3), 175-186, 2015 | 39 | 2015 |
